不同淀粉样蛋白免疫检测与视觉淀粉样蛋白PET评估的一致性
该研究纳入262例轻度认知障碍或主观认知下降患者,比较5种脑脊液Aβ42免疫检测与视觉[18F]flutemetamol PET状态的一致性。新检测与质谱参考方法相关性更高,但经典INNOTEST与PET一致性最佳;使用Aβ42:Aβ40或Aβ42:tau比值可显著提高新检测的准确性。
要点
- 新免疫检测与质谱参考方法相关性优于经典INNOTEST。
- 经典INNOTEST与视觉PET一致性AUC为0.92,优于新检测的0.87-0.89。
- 采用Aβ42:Aβ40或Aβ42:tau比值可提高新检测与PET的一致性。
核心结论
- 新免疫检测的脑脊液Aβ42与质谱参考方法相关性更好,使用Aβ42:Aβ40或Aβ42:tau比值可改善与视觉PET评估的一致性。
研究设计与样本
- 研究纳入262例来自瑞典BioFINDER队列的轻度认知障碍或主观认知下降患者,均接受[18F]flutemetamol PET。
- 脑脊液Aβ42使用经典INNOTEST、改良INNOTEST、Lumipulse、EUROIMMUN和Meso Scale Discovery五种免疫检测分析。
- 以抗体非依赖的质谱参考测量程序评估脑脊液Aβ浓度。
主要发现
- 质谱法Aβ42与改良INNOTEST(r=0.97)、Lumipulse(r=0.93)、EUROIMMUN(r=0.93)和MSD(r=0.95)的相关性高于经典INNOTEST(r=0.88;P≤.01)。
- 经典INNOTEST与视觉PET状态的一致性AUC为0.92,优于新检测的AUC 0.87-0.89(P≤.01)。
- 新检测使用Aβ42:Aβ40比值后AUC提高至0.93-0.95(P≤.01),使用Aβ42:T-tau比值后AUC为0.94(P≤.05),使用Aβ42:P-tau比值后AUC为0.94-0.95(P≤.001)。
- Aβ42:Aβ40比值联合T-tau或P-tau水平并未比单独使用比值进一步改善准确性。
临床怎么用
- 临床和试验中可考虑采用脑脊液Aβ42:Aβ40或Aβ42:tau比值作为淀粉样蛋白沉积的生物标志物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Visual assessment of amyloid positron emission tomographic (PET) images has been approved by regulatory authorities for clinical use. Several immunoassays have been developed to measure β-amyloid (Aβ) 42 in cerebrospinal fluid (CSF). The agreement between CSF Aβ42 measures from different immunoassays and visual PET readings may influence the use of CSF biomarkers and/or amyloid PET assessment in clinical practice and trials. OBJECTIVE: To determine the concordance between CSF Aβ42 levels measured using 5 different immunoassays and visual amyloid PET analysis. DESIGN, SETTING, AND PARTICIPANTS: The study included 262 patients with mild cognitive impairment or subjective cognitive decline from the Swedish BioFINDER (Biomarkers for Identifying Neurodegenerative Disorders Early and Reliably) cohort (recruited from September 1, 2010, through December 31, 2014) who had undergone flutemetamol F 18 ([18F]flutemetamol)-labeled PET. Levels of CSF Aβ42 were analyzed using the classic INNOTEST and the newer modified INNOTEST, fully automated Lumipulse (FL), EUROIMMUN (EI), and Meso Scale Discovery (MSD) assays. Concentrations of CSF Aβ were assessed using an antibody-independent mass spectrometry-based reference measurement procedure. MAIN OUTCOMES AND MEASURES: The concordance of CSF Aβ42 levels and Aβ42:Aβ40 and Aβ42:tau ratios with visual [18F]flutemetamol PET status. RESULTS: Of 262 participants (mean [SD] age, 70.9 [5.5] years), 108 were women (41.2%) and 154 were men (58.8%). The mass spectrometry-derived Aβ42 values showed higher correlations with the modified Aβ42-INNOTEST (r = 0.97), Aβ42-FL (r = 0.93), Aβ42-EI (r = 0.93), and Aβ42-MSD (r = 0.95) assays compared with the classic Aβ42-INNOTEST assay (r = 0.88; P ≤ .01). The signal in the classic Aβ42-INNOTEST assay was partly quenched by recombinant Aβ1-40 peptide. However, the classic Aβ42-INNOTEST assay showed better concordance with visual [18F]flutemetamol PET status (area under the receiver operating characteristic curve [AUC], 0.92) compared with the newer assays (AUCs, 0.87-0.89; P ≤ .01). The accuracies of the newer assays improved significantly when Aβ42:Aβ40 (AUCs, 0.93-0.95; P ≤ .01), Aβ42 to total tau (T-tau) (AUCs, 0.94; P ≤ .05), or Aβ42 to phosphorylated tau (P-tau) (AUCs, 0.94-0.95; P ≤ .001) ratios were used. A combination of the Aβ42:Aβ40 ratio and T-tau or P-tau level did not improve the accuracy compared with the ratio alone. CONCLUSIONS AND RELEVANCE: Concentrations of CSF Aβ42 derived from the new immunoassays (modified INNOTEST, FL, EI, and MSD) may correlate better with the antibody-independent mass spectrometry-based reference measurement procedure and may show improved agreement with visual [18F]flutemetamol PET assessment when using the Aβ42:Aβ40 or Aβ42:tau ratios. These findings suggest the benefit of implementing the CSF Aβ42:Aβ40 or Aβ42:tau ratios as a biomarker of amyloid deposition in clinical practice and trials.
引用
- Janelidze S, Pannee J, Mikulskis A, et al. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. JAMA Neurol. 2017. PMID: 29114726. doi:10.1001/jamaneurol.2017.2814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。